<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997714/" ref="ordinalpos=2269&amp;ncbi_uid=6056255&amp;link_uid=PMC3997714" image-link="/pmc/articles/PMC3997714/figure/f3-ol-07-05-1345/" class="imagepopup">Figure 3.  From: Autophagy: A novel therapeutic target for hepatocarcinoma (Review). </a></div><br /><div class="p4l_captionBody">Sorafenib activates autophagy through different signaling pathways. Autophagic cell death is triggered by sorafenib by suppressing myeloid cell leukemia-1 (Mcl-1)-related signaling pathway in hepatocarcinoma (HCC) PLC5, SK-Hep1, HepG2 and Hep3B cells (53). Thus, inducers of autophagy may be used in combination with sorafenib to promote anti-cancer efficacy. Cytoprotective autophagy is triggered by sorafenib through endoplasmic reticulum (ER) or the Akt/mTOR signaling pathway in MHCC97-L and PLC/PRF/5 cells (47,48). Inhibitors of autophagy may therefore be used in combination with sorafenib to promote anti-cancer efficacy.</div></div>